These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 26856820)

  • 1. St Gallen molecular subtypes in screening-detected and symptomatic breast cancer in a prospective cohort with long-term follow-up.
    Falck AK; Röme A; Fernö M; Olsson H; Chebil G; Bendahl PO; Rydén L
    Br J Surg; 2016 Apr; 103(5):513-23. PubMed ID: 26856820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up.
    Falck AK; Bendahl PO; Chebil G; Olsson H; Fernö M; Rydén L
    Breast Cancer Res Treat; 2013 Jul; 140(1):93-104. PubMed ID: 23807420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. St Gallen molecular subtypes in primary breast cancer and matched lymph node metastases--aspects on distribution and prognosis for patients with luminal A tumours: results from a prospective randomised trial.
    Falck AK; Fernö M; Bendahl PO; Rydén L
    BMC Cancer; 2013 Nov; 13():558. PubMed ID: 24274821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interval Breast Cancer Versus Screen-Detected Cancer: Comparison of Clinicopathologic Characteristics in a Single-Center Analysis.
    Bellio G; Marion R; Giudici F; Kus S; Tonutti M; Zanconati F; Bortul M
    Clin Breast Cancer; 2017 Nov; 17(7):564-571. PubMed ID: 28456487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
    Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
    Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does breast screening offer a survival benefit? A retrospective comparative study of oncological outcomes of screen-detected and symptomatic early stage breast cancer cases.
    Újhelyi M; Pukancsik D; Kelemen P; Kovács E; Kenessey I; Udvarhelyi N; Bak M; Kovács T; Mátrai Z
    Eur J Surg Oncol; 2016 Dec; 42(12):1814-1820. PubMed ID: 27424787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of adhesion proteins E-cadherin, alpha-catenin, beta-catenin and gamma-catenin is different in T1 and T2 breast tumours.
    Bukholm IR; Nesland JM; Bukholm G
    Pathology; 2006 Oct; 38(5):403-7. PubMed ID: 17008277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclin B1 is a prognostic proliferation marker with a high reproducibility in a population-based lymph node negative breast cancer cohort.
    Niméus-Malmström E; Koliadi A; Ahlin C; Holmqvist M; Holmberg L; Amini RM; Jirström K; Wärnberg F; Blomqvist C; Fernö M; Fjällskog ML
    Int J Cancer; 2010 Aug; 127(4):961-7. PubMed ID: 19957331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between molecular metastases in sentinel lymph nodes of breast cancer patients and St Gallen risk category.
    Gimbergues P; Dauplat MM; Cayre A; Durando X; Le Bouedec G; Finat-Duclos F; Portefaix G; Kwiatkowski F; Dauplat J; Penault-Llorca F; Tchirkov A
    Eur J Surg Oncol; 2007 Feb; 33(1):16-22. PubMed ID: 17071045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of age, intrinsic subtype and local treatment on long-term local-regional recurrence and breast cancer mortality among low-risk breast cancer patients.
    Laurberg T; Alsner J; Tramm T; Jensen V; Lyngholm CD; Christiansen PM; Overgaard J
    Acta Oncol; 2017 Jan; 56(1):59-67. PubMed ID: 27846764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison between screen-detected and symptomatic breast cancers according to molecular subtypes.
    Kim J; Lee S; Bae S; Choi MY; Lee J; Jung SP; Kim S; Choe JH; Kim JH; Kim JS; Lee JE; Nam SJ; Yang JH
    Breast Cancer Res Treat; 2012 Jan; 131(2):527-40. PubMed ID: 22042364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of clinical-pathological characteristics between symptomatic and interval breast cancer.
    Meshkat B; Prichard RS; Al-Hilli Z; Bass GA; Quinn C; O'Doherty A; Rothwell J; Geraghty J; Evoy D; McDermott EW
    Breast; 2015 Jun; 24(3):278-82. PubMed ID: 25771080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term follow-up study of a prospective multicenter sentinel node trial: molecular detection of breast cancer sentinel node metastases.
    Verbanac KM; Min CJ; Mannie AE; Lu J; O'Brien KF; Rosman M; Tafra L;
    Ann Surg Oncol; 2010 Oct; 17 Suppl 3():368-77. PubMed ID: 20853060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormone receptors and HER2 expression in primary breast carcinoma and corresponding lymph node metastasis: do we need both?
    Raica M; Cîmpean AM; Ceausu RA; Fulga V; Nica C; Rudico L; Saptefrati L
    Anticancer Res; 2014 Mar; 34(3):1435-40. PubMed ID: 24596391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraoperative molecular assay for sentinel lymph node metastases in early stage breast cancer: a comparative analysis between one-step nucleic acid amplification whole node assay and routine frozen section histology.
    Osako T; Iwase T; Kimura K; Yamashita K; Horii R; Yanagisawa A; Akiyama F
    Cancer; 2011 Oct; 117(19):4365-74. PubMed ID: 21437889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Dutch Prediction Tool to Assess the Risk of Additional Axillary Non-Sentinel Lymph Node Involvement in Sentinel Node-Positive Breast Cancer Patients.
    van den Hoven I; van Klaveren D; Voogd AC; Vergouwe Y; Tjan-Heijnen V; Roumen RM
    Clin Breast Cancer; 2016 Apr; 16(2):123-30. PubMed ID: 26602438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of intermediate measures from a population-based, randomized trial of mammographic screening prevalence and detection of breast carcinoma among Asian women: the Singapore Breast Screening Project.
    Ng EH; Ng FC; Tan PH; Low SC; Chiang G; Tan KP; Seow A; Emmanuel S; Tan CH; Ho GH; Ng LT; Wilde CC
    Cancer; 1998 Apr; 82(8):1521-8. PubMed ID: 9554530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological parameters and biological markers predicting non-sentinel node metastasis in sentinel node-positive breast cancer patients.
    Kwon Y; Ro J; Kang HS; Kim SK; Hong EK; Khang SK; Gong G; Ro JY
    Oncol Rep; 2011 Apr; 25(4):1063-71. PubMed ID: 21258771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential TAG-72 epitope expression in breast cancer and lymph node metastases: a marker of a more aggressive phenotype.
    Galietta A; Pizzi C; Pettinato G; Limite G; Sgambato A; Lamberti M; Muraro R; Formisano C; Pensabene M; Bianco AR; Mariani-Costantini R; Contegiacomo A
    Oncol Rep; 2002; 9(1):135-40. PubMed ID: 11748471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mode of detection: an independent prognostic factor for women with breast cancer.
    Hofvind S; Holen Å; Román M; Sebuødegård S; Puig-Vives M; Akslen L
    J Med Screen; 2016 Jun; 23(2):89-97. PubMed ID: 26582492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.